Furthermore, the stratification of immune phenotype based on pre-treatment CCR8+ Treg cells and CXCL13+ Tex cells in EGFR-mutant NSCLC requires a larger sample size to further illustrate its predictive value for immunotherapy. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.